In 2023, the United States generic injectables market reached an impressive valuation of nearly USD 15.07 billion. This dynamic industry is projected to grow at a steady CAGR of 7% from 2024 to 2032, anticipated to attain a remarkable value of approximately USD 27.76 billion by the end of 2032.